Sen. Markwayne Mullin Purchases Shares of Boston Scientific Corporation (NYSE:BSX)

Senator Markwayne Mullin (R-Oklahoma) recently bought shares of Boston Scientific Corporation (NYSE:BSX). In a filing disclosed on January 16th, the Senator disclosed that they had bought between $15,001 and $50,000 in Boston Scientific stock on December 29th.

Senator Markwayne Mullin also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Deere & Company (NYSE:DE) on 12/29/2025.
• Purchased $15,001 – $50,000 in shares of Hilton Worldwide (NYSE:HLT) on 12/29/2025.
• Purchased $15,001 – $50,000 in shares of RTX (NYSE:RTX) on 12/29/2025.
• Purchased $15,001 – $50,000 in shares of CocaCola (NYSE:KO) on 12/29/2025.
• Purchased $15,001 – $50,000 in shares of Elevance Health (NYSE:ELV) on 12/29/2025.
• Purchased $1,001 – $15,000 in shares of American Express (NYSE:AXP) on 12/29/2025.
• Purchased $100,001 – $250,000 in shares of Amazon.com (NASDAQ:AMZN) on 12/29/2025.
• Purchased $50,001 – $100,000 in shares of JPMorgan Chase & Co. (NYSE:JPM) on 12/29/2025.
• Purchased $15,001 – $50,000 in shares of The Goldman Sachs Group (NYSE:GS) on 12/29/2025.
• Purchased $15,001 – $50,000 in shares of Home Depot (NYSE:HD) on 12/29/2025.

Boston Scientific Stock Down 2.1%

Shares of NYSE:BSX traded down $1.90 during midday trading on Friday, hitting $88.13. 17,376,232 shares of the company’s stock traded hands, compared to its average volume of 7,666,439. The firm’s fifty day moving average price is $96.90 and its two-hundred day moving average price is $100.29. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. Boston Scientific Corporation has a twelve month low of $85.98 and a twelve month high of $109.50. The company has a market cap of $130.65 billion, a PE ratio of 47.13, a P/E/G ratio of 1.56 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The company had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. During the same quarter in the previous year, the firm posted $0.63 earnings per share. The firm’s quarterly revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, equities research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Hedge Funds Weigh In On Boston Scientific

Several institutional investors have recently made changes to their positions in the stock. FWL Investment Management LLC acquired a new position in Boston Scientific during the 2nd quarter valued at approximately $26,000. Sound Income Strategies LLC lifted its stake in Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 120 shares during the last quarter. Steph & Co. acquired a new position in shares of Boston Scientific during the third quarter valued at $25,000. Murphy & Mullick Capital Management Corp grew its position in shares of Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 170 shares during the last quarter. Finally, Financial Consulate Inc. acquired a new stake in shares of Boston Scientific in the 3rd quarter worth about $25,000. 89.07% of the stock is owned by institutional investors.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Acquisition expands addressable market — The agreement to buy Penumbra (~$14.5B enterprise value) gives Boston Scientific scaled entry into mechanical thrombectomy and neurovascular devices, which management says accelerates growth in fast-growing vascular segments. Read More.
• Positive Sentiment: Wall Street support remains — TD Cowen reiterated a Buy and other analysts emphasize the deal as a strategic growth catalyst and valuation support ahead of 2026 expectations. Read More.
• Neutral Sentiment: Price-target and analyst notes are mixed — Oppenheimer trimmed its target from $125 to $100 but kept an Outperform rating, indicating continued upside though with more cautious near-term expectations. Read More.
• Neutral Sentiment: Technical/turnaround commentary — Some market commentators note BSX is technically oversold and that consensus earnings revisions are turning positive, which could support a rebound over time. Read More.
• Neutral Sentiment: Smaller tuck-ins continue — Boston Scientific’s other recent deals (e.g., Valencia Technologies) broaden product offerings in urology and ITNS, a modest near-term boost versus the Penumbra scale. Read More.
• Negative Sentiment: Shares sold off on the deal announcement — The market reacted negatively to the size/structure of the transaction and near-term uncertainty, and BSX shares traded down after the news. Read More.
• Negative Sentiment: Legal/approval uncertainty — Law firms have launched investor inquiries into the adequacy of Penumbra’s sale process and price; this increases deal execution risk and could prolong integration or regulatory review. Read More.
• Negative Sentiment: Derivative-market hedging and bearish interest spiked — Unusually large put option volume indicates some investors are hedging or betting on further downside, adding volatility risk. Read More.
• Negative Sentiment: Mixed analyst commentary and skeptic pieces — Several independent commentaries and Seeking Alpha pieces highlight concerns about price paid and strategic fit, underscoring near-term skepticism despite long-term promise. Read More.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Canaccord Genuity Group reduced their target price on shares of Boston Scientific from $132.00 to $131.00 and set a “buy” rating on the stock in a research report on Wednesday, December 17th. Robert W. Baird lifted their price objective on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. The Goldman Sachs Group reiterated a “buy” rating and set a $112.00 target price on shares of Boston Scientific in a research note on Friday, January 9th. Cowen reissued a “buy” rating on shares of Boston Scientific in a research report on Thursday, December 11th. Finally, Barclays upped their price target on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a report on Thursday, October 2nd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, Boston Scientific presently has an average rating of “Buy” and an average price target of $123.89.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,396,580. This represents a 42.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Ellen M. Zane sold 12,891 shares of the stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total value of $1,266,927.48. Following the completion of the transaction, the director directly owned 24,134 shares of the company’s stock, valued at approximately $2,371,889.52. The trade was a 34.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 93,095 shares of company stock valued at $9,305,450 in the last ninety days. Company insiders own 0.50% of the company’s stock.

About Senator Mullin

Markwayne Mullin (Republican Party) is a member of the U.S. Senate from Oklahoma. He assumed office on January 11, 2023. His current term ends on January 3, 2027. Mullin (Republican Party) ran in a special election to the U.S. Senate to represent Oklahoma. He won in the special general election on November 8, 2022. Mullin is a member of the Cherokee Nation and one of four Native American members of the 116th Congress. At the age of 20, Mullin took over his father’s plumbing business. He is also a former professional mixed martial artist. Markwayne Mullin graduated from Stilwell High School. Mullin earned an associate degree in construction technology from Oklahoma State University Institute of Technology. His career experience includes owning and founding multiple businesses.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.